3432-80-2

Upstream product

• 177784-37-1 2-bromo-N-(2-cyclohexanecarbonyl-phenyl)-acetamide 
• 1885-29-6 anthranilic acid nitrile 
• 3432-87-9 (2-aminophenyl)cyclohexylmethanone 
• 108-85-0 1-bromocyclohexane 

Downstream Products

• 713517-34-1 5-cyclohexyl-1-(4-methoxy-benzyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one 

Relevant academic research and scientific papers

Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists

Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ET A/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo[e] [1,4]diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.